TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that new data on TRC105 and TRC102 will be presented at the 22nd Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.
TRC105 and TRC102 are both novel, first-in-class, clinical stage cancer therapies. TRC105 is an IgG1 monoclonal antibody to CD105 (endoglin), an endothelial cell receptor that is essential for the process of new blood vessel formation called angiogenesis. TRC102 is a small molecule inhibitor of base excision repair that reverses resistance to commonly used antimetabolite and alkylating agent chemotherapies.
The presentation details are as follows:
Abstract #367 — A first-in-human Phase 1 study of anti-CD105 antibody therapy with TRC105 in patients with advanced solid tumors
Thursday, Nov 18, 2010, 12:00 pm to 2:20 pm (Poster Session PP19 – Molecular-targeted therapies-clinical trials)
Abstract #517 — Combining pemetrexed with temozolomide and TRC102 (methoxyamine) causes synergistic cytotoxicity in melanoma cells
Friday, Nov 19, 2010 – 8:00 am to 9:30 am (Poster Session PP12 – DNA repair and inhibitors)
After the meeting, the poster presentations will be available on TRACON’s corporate website (www.traconpharma.com).
Source: TRACON Pharmaceuticals, Inc.